ArticleCancer2023

Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer.

Blessie Elizabeth Nelson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.